Correction to: HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 studyPAINIn Abstract, under the section "Results", the first and third p values are incorrect. The correct p values should be p = 0.0004 and p < ...
Correction to: HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study (Hernia, (2019), 23, 6, (1071-1080), 10.1007/s10029-019-02023-6)doi:10.1007/s10029-020-02134-5E. Viscusi...
In a prior phase 3 inguinal herniorrhaphy study, HTX-011 alone provided superior pain relief for 72 hours and significantly decreased opioid use compared with saline placebo and bupivacaine hydrochloride. This open-label study assessed the safety, efficacy, and opioid-sparing properties of HTX-011 ...